Prevention of Chyle-leak After Major Pancreatic Surgery
Launched by HELSINKI UNIVERSITY CENTRAL HOSPITAL · May 24, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at ways to prevent a condition called chyle leak, which can happen after major pancreatic surgery. Chyle is a fluid that contains important nutrients and is part of the body’s lymphatic system. When the lymphatic vessels are damaged during surgery, some patients may experience a chyle leak, which can lead to serious issues like dehydration and infections. In this study, researchers are comparing two groups of patients: one group will start a special diet without fats right after surgery, while the other group will only begin this diet if they develop a chyle leak. The goal is to see if starting the diet early can help reduce the chances of having a chyle leak and improve recovery.
To participate in this study, you need to be scheduled for pancreatic surgery that involves removing part of the pancreas and possibly repairing nearby blood vessels. Unfortunately, if you don’t need this type of surgery or if you decide not to take part, you won't be eligible. If you join, you can expect close monitoring during your recovery and help with your diet to see how it affects your healing. This trial is currently recruiting participants from various age groups and welcomes anyone regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Need for a pancreatic resection with vessel resection/reconstruction
- Exclusion Criteria:
- • No pancreatic and vessel resection needed
- • Patients do not want to join the study
About Helsinki University Central Hospital
Helsinki University Central Hospital (HUCH) is a leading academic medical institution in Finland, dedicated to advancing healthcare through innovative research and clinical excellence. As a pivotal sponsor of clinical trials, HUCH integrates cutting-edge medical practices with rigorous scientific inquiry, fostering collaborations between researchers, healthcare professionals, and patients. The hospital is committed to enhancing patient outcomes and contributing to the global body of medical knowledge by conducting high-quality, ethically sound clinical studies across a diverse range of therapeutic areas. With a strong emphasis on education and training, HUCH plays a vital role in shaping the next generation of healthcare leaders and researchers.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, , Finland
Patients applied
Trial Officials
Hanna Seppänen, Phd, Dos
Principal Investigator
Helsinki University Central Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials